title: Phenotypic and functional analysis of human SLC26A6 variants in patients with familial hyperoxaluria and calcium oxalate nephrolithiasis.
abstract: BACKGROUND
  Urinary oxalate is a major risk factor for calcium oxalate stones. Marked hyperoxaluria arises from mutations in 2 separate loci, AGXT and GRHPR, the causes of primary hyperoxaluria (PH) types 1 (PH1) and 2 (PH2), respectively. Studies of null Slc26a6(-/-) mice have shown a phenotype of hyperoxaluria, hyperoxalemia, and calcium oxalate urolithiasis, leading to the hypothesis that SLC26A6 mutations may cause or modify hyperoxaluria in humans.
  
  
  METHODS
  Cross-sectional case-control.
  
  
  METHODS
  Cases were recruited from the International Primary Hyperoxaluria Registry. Control DNA samples were from a pool of adult subjects who identified themselves as being in good health.
  
  
  METHODS
  PH1, PH2, and non-PH1/PH2 genotypes in cases.
  
  
  METHODS
  Homozygosity or compound heterozygosity for SLC26A6 variants. Functional expression of oxalate transport in Xenopus laevis oocytes.
  
  
  RESULTS
  80 PH1, 6 PH2, 8 non-PH1/PH2, and 96 control samples were available for SLC26A6 screening. A rare variant, c.487C-->T (p.Pro163Ser), was detected solely in 1 non-PH1/PH2 pedigree, but this variant failed to segregate with hyperoxaluria, and functional studies of oxalate transport in Xenopus oocytes showed no transport defect. No other rare variant was identified specifically in non-PH1/PH2. Six additional missense variants were detected in controls and cases. Of these, c.616G-->A (p.Val206Met) was most common (11%) and showed a 30% reduction in oxalate transport. To test p.Val206Met as a potential modifier of hyperoxaluria, we extended screening to PH1 and PH2. Heterozygosity for this variant did not affect plasma or urine oxalate levels in this population.
  
  
  CONCLUSIONS
  We did not have a sufficient number of cases to determine whether homozygosity for p.Val206Met might significantly affect urine oxalate.
  
  
  CONCLUSIONS
  SLC26A6 was effectively ruled out as the disease gene in this non-PH1/PH2 cohort. Taken together, our studies are the first to identify and characterize SLC26A6 variants in patients with hyperoxaluria. Phenotypic and functional analysis excluded a significant effect of identified variants on oxalate excretion.
authors.affiliation: Mayo Clinic Hyperoxaluria Center, Division of Nephrology and Hypertension, Departments of Internal Medicine and Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, MN 55905, USA. monico.carla@mayo.edu
authors.forename: Carla G
authors.initials: CG
authors.lastname: Monico
authors.forename: Adam
authors.initials: A
authors.lastname: Weinstein
authors.forename: Zhirong
authors.initials: Z
authors.lastname: Jiang
authors.forename: Audrey L
authors.initials: AL
authors.lastname: Rohlinger
authors.forename: Andrea G
authors.initials: AG
authors.lastname: Cogal
authors.forename: Beth B
authors.initials: BB
authors.lastname: Bjornson
authors.forename: Julie B
authors.initials: JB
authors.lastname: Olson
authors.forename: Eric J
authors.initials: EJ
authors.lastname: Bergstralh
authors.forename: Dawn S
authors.initials: DS
authors.lastname: Milliner
authors.forename: Peter S
authors.initials: PS
authors.lastname: Aronson
mesh_terms: D000293:Adolescent; D000328:Adult; D002129:Calcium Oxalate / Q000378:metabolism; D016022:Case-Control Studies; D002675:Child, Preschool; D003430:Cross-Sectional Studies; D005260:Female; D006801:Humans; D053565:Hypercalciuria / Q000235:genetics*; D008297:Male; D026901:Membrane Transport Proteins / Q000235:genetics*; D008875:Middle Aged; D009154:Mutation; D053040:Nephrolithiasis / Q000235:genetics* / Q000378:metabolism; D010375:Pedigree; D010641:Phenotype; D000076988:Sulfate Transporters; D055815:Young Adult
chemical_list: D026901:Membrane Transport Proteins; C439529:SLC26A6 protein, human; D000076988:Sulfate Transporters; D002129:Calcium Oxalate